GTCR Sells Corza Medical's Biosurgery Unit to EQT
GTCR announced on July 7, 2026, the divestiture of Corza Medical's Biosurgery business unit to EQT. The sale aims to support the biosurgery unit's future growth under new ownership.
GTCR, a private equity firm, has completed the sale of Corza Medical's Biosurgery business unit to investment organization EQT. The transaction, announced July 7, 2026, marks a strategic shift for both entities, enabling Corza Medical to direct resources toward its other core surgical technology segments.
Corza Medical will now focus its investments on its Wound Closure, Ophthalmology, and Biomedical Textiles divisions. This restructuring allows the company to concentrate on expanding its presence and product offerings within these specialized medical fields. The Biosurgery unit, acquired by EQT, is expected to pursue its own growth trajectory independently.
The divestiture suggests a strategic realignment within the medical technology sector, as private equity firms often adjust portfolios to optimize growth and returns. EQT's acquisition of the Biosurgery unit indicates confidence in its market potential and future profitability.
Further details regarding the financial terms of the transaction were not immediately disclosed. Both GTCR and EQT are known for their active participation in the healthcare and technology investment landscape.